Canaccord Genuity analyst Kyle Rose reiterated a Buy rating on AxoGen (AXGN – Research Report) today and set a price target of $15.00. The company’s shares closed yesterday at $9.22.
Rose covers the Healthcare sector, focusing on stocks such as Globus Medical, Stryker, and Alphatec Holdings. According to TipRanks, Rose has an average return of 13.6% and a 50.32% success rate on recommended stocks.
In addition to Canaccord Genuity, AxoGen also received a Buy from JMP Securities’s David Turkaly in a report issued on March 15. However, on March 14, BTIG maintained a Hold rating on AxoGen (NASDAQ: AXGN).
See Insiders’ Hot Stocks on TipRanks >>
Based on AxoGen’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $36.16 million and a GAAP net loss of $5.42 million. In comparison, last year the company earned a revenue of $31.54 million and had a GAAP net loss of $5.29 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AxoGen, Inc. engages in the development and market of surgical solutions for peripheral nerves. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. Its products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.
Read More on AXGN:
- Axogen, Inc Reports 2022 Fourth Quarter and Full-Year Financial Results
- AxoGen sees FY23 revenue $154M-$159M, consensus $158.94M
- AxoGen reports Q4 adjusted EPS (3c), consensus (11c)
- AxoGen appoints Began as EVP, General Counsel
- Axogen, Inc. Appoints Marc Began as Executive Vice President and General Counsel
